Diamond Biotechnology Co., Ltd

TPEX:6815 Rapporto sulle azioni

Cap. di mercato: NT$2.6b

Diamond Biotechnology Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Diamond Biotechnology has a total shareholder equity of NT$612.6M and total debt of NT$301.9M, which brings its debt-to-equity ratio to 49.3%. Its total assets and total liabilities are NT$1.0B and NT$428.9M respectively. Diamond Biotechnology's EBIT is NT$98.7M making its interest coverage ratio 13.6. It has cash and short-term investments of NT$224.1M.

Informazioni chiave

49.3%

Rapporto debito/patrimonio netto

NT$301.86m

Debito

Indice di copertura degli interessi13.6x
ContantiNT$224.14m
Patrimonio nettoNT$612.55m
Totale passivitàNT$428.90m
Totale attivitàNT$1.04b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: 6815's short term assets (NT$673.3M) exceed its short term liabilities (NT$231.8M).

Passività a lungo termine: 6815's short term assets (NT$673.3M) exceed its long term liabilities (NT$197.1M).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 6815's net debt to equity ratio (12.7%) is considered satisfactory.

Riduzione del debito: 6815's debt to equity ratio has increased from 37.8% to 49.3% over the past 5 years.

Copertura del debito: 6815's operating cash flow is negative, therefore debt is not well covered.

Copertura degli interessi: 6815's interest payments on its debt are well covered by EBIT (13.6x coverage).


Bilancio


Scoprire le aziende sane